Cardioprotection by the inhibitory effect of nitric oxide.
- Author:
Zhi-Jie YUE
1
;
Zhi-Bin YU
Author Information
1. Department of Aerospace Physiology, the Fourth Military Medical University, Xi'an, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Cardiotonic Agents;
Depression, Chemical;
Humans;
Mitochondria, Heart;
metabolism;
Mitochondrial Membrane Transport Proteins;
physiology;
Myocardial Contraction;
physiology;
Myocytes, Cardiac;
enzymology;
Nitric Oxide;
physiology;
Nitric Oxide Synthase;
metabolism;
Oxygen Consumption;
physiology;
Ryanodine Receptor Calcium Release Channel;
physiology
- From:
Acta Physiologica Sinica
2011;63(3):191-197
- CountryChina
- Language:Chinese
-
Abstract:
Endothelial and neuronal nitric oxide synthases (eNOS and nNOS) are constitutively expressed in cardiomyocytes under the physiological condition, while inducible nitric oxide synthase (iNOS) is only expressed in cell stress. Nitric oxide (NO) derived from the constitutive isoforms of eNOS and nNOS plays four kinds of inhibitory effects on the myocardium: reducing the contractile frequency of cardiomyocyte, slightly attenuating cardiac contractility, accelerating relaxation and increasing distensibility of cardiomyocyte, and slightly inhibiting mitochondrial respiration and improving the efficiency of myocardial oxygen consumption. In conditions of enhanced cardiac reserve and cardiac hypertrophy, NO derived from eNOS, which forms a complex with a certain kind of receptor on the sarcolemma, modulates receptor-mediated signaling and generates an "accentuated antagonism" by moderate inhibition of cardiac contractility. NO derived from the complex of nNOS-ryanodine receptor (RyR) stabilizes RyR calcium release and increases the efficiency of Ca(2+) cycling in sarcoplasmic reticulum by the inhibitory effects. However, besides the above-mentioned inhibitions of NO derived from eNOS and nNOS, NO derived from iNOS generally prevents mitochondrial permeability transition pore opening by inhibiting mitochondrial respiration under the conditions of the myocardial ischemia-reperfusion injury and heart failure. Therefore, both in the physiological condition and in the pathological condition, NO exhibits a moderate inhibition in cardiac function, and eventually produces cardioprotection.
